279.5 USD
+6.91 (+2.53%)
279.5 USD
0 (0%)
CME gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 235 industry peers in the Capital Markets industry. While CME has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, CME is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year CME was profitable.
- CME had a positive operating cash flow in the past year.
- CME had positive earnings in each of the past 5 years.
- CME had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of 1.99%, CME perfoms like the industry average, outperforming 45.96% of the companies in the same industry.
- CME's Return On Equity of 13.18% is fine compared to the rest of the industry. CME outperforms 72.77% of its industry peers.
- CME's Return On Invested Capital of 18.72% is amongst the best of the industry. CME outperforms 95.74% of its industry peers.
- CME had an Average Return On Invested Capital over the past 3 years of 15.81%. This is significantly above the industry average of 7.16%.
- The 3 year average ROIC (15.81%) for CME is below the current ROIC(18.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROIC | 18.72% |
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
1.3 Margins
- With a decent Profit Margin value of 32.91%, CME is doing good in the industry, outperforming 79.57% of the companies in the same industry.
- In the last couple of years the Profit Margin of CME has declined.
- CME has a Operating Margin of 80.16%. This is amongst the best in the industry. CME outperforms 98.72% of its industry peers.
- CME's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A |
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CME has about the same amout of shares outstanding than it did 1 year ago.
- Compared to 5 years ago, CME has more shares outstanding
- Compared to 1 year ago, CME has an improved debt to assets ratio.
2.2 Solvency
- CME has a debt to FCF ratio of 0.84. This is a very positive value and a sign of high solvency as it would only need 0.84 years to pay back of all of its debts.
- The Debt to FCF ratio of CME (0.84) is better than 89.36% of its industry peers.
- A Debt/Equity ratio of 0.12 indicates that CME is not too dependend on debt financing.
- With a decent Debt to Equity ratio value of 0.12, CME is doing good in the industry, outperforming 79.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.84 | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.02 indicates that CME should not have too much problems paying its short term obligations.
- CME has a Current ratio of 1.02. This is comparable to the rest of the industry: CME outperforms 45.96% of its industry peers.
- CME has a Quick Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
- CME has a Quick ratio (1.02) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 8.41% over the past year.
- Measured over the past years, CME shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.57% on average per year.
- Looking at the last year, CME shows a quite strong growth in Revenue. The Revenue has grown by 10.03% in the last year.
- Measured over the past years, CME shows a quite strong growth in Revenue. The Revenue has been growing by 13.14% on average per year.
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%
3.2 Future
- CME is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.92% yearly.
- The Revenue is expected to grow by 4.71% on average over the next years.
EPS Next Y9.98%
EPS Next 2Y7.13%
EPS Next 3Y6.89%
EPS Next 5Y7.92%
Revenue Next Year6.33%
Revenue Next 2Y5.53%
Revenue Next 3Y5.51%
Revenue Next 5Y4.71%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 25.50, the valuation of CME can be described as expensive.
- Based on the Price/Earnings ratio, CME is valued a bit more expensive than 62.55% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.47, CME is valued at the same level.
- Based on the Price/Forward Earnings ratio of 23.74, the valuation of CME can be described as rather expensive.
- CME's Price/Forward Earnings ratio is in line with the industry average.
- When comparing the Price/Forward Earnings ratio of CME to the average of the S&P500 Index (24.26), we can say CME is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.5 | ||
| Fwd PE | 23.74 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CME indicates a rather cheap valuation: CME is cheaper than 87.66% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, CME is valued a bit cheaper than the industry average as 60.85% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.68 | ||
| EV/EBITDA | 10.55 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CME does not grow enough to justify the current Price/Earnings ratio.
- CME has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.55
PEG (5Y)2.97
EPS Next 2Y7.13%
EPS Next 3Y6.89%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.88%, CME has a reasonable but not impressive dividend return.
- CME's Dividend Yield is comparable with the industry average which is at 6.15.
- CME's Dividend Yield is comparable with the S&P500 average which is at 1.89.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.88% |
5.2 History
- The dividend of CME is nicely growing with an annual growth rate of 16.00%!
- CME has been paying a dividend for at least 10 years, so it has a reliable track record.
- CME has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)16%
Div Incr Years11
Div Non Decr Years11
5.3 Sustainability
- CME pays out 104.85% of its income as dividend. This is not a sustainable payout ratio.
- CME's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP104.85%
EPS Next 2Y7.13%
EPS Next 3Y6.89%
279.5
+6.91 (+2.53%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)10-22 2025-10-22/bmo
Earnings (Next)02-04 2026-02-04/amc
Inst Owners91.62%
Inst Owner Change-0.14%
Ins Owners0.24%
Ins Owner Change-0.44%
Market Cap100.79B
Revenue(TTM)11.29B
Net Income(TTM)3.72B
Analysts70
Price Target291.65 (4.35%)
Short Float %1.72%
Short Ratio3.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.88% |
Yearly Dividend9.97
Dividend Growth(5Y)16%
DP104.85%
Div Incr Years11
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.59%
Min EPS beat(2)0.43%
Max EPS beat(2)0.76%
EPS beat(4)3
Avg EPS beat(4)0.49%
Min EPS beat(4)-1.28%
Max EPS beat(4)2.05%
EPS beat(8)6
Avg EPS beat(8)0.72%
EPS beat(12)10
Avg EPS beat(12)0.95%
EPS beat(16)14
Avg EPS beat(16)1.13%
Revenue beat(2)0
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-1.11%
Max Revenue beat(2)-0.54%
Revenue beat(4)0
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.54%
Revenue beat(8)0
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)7.34%
Revenue beat(16)7
Avg Revenue beat(16)10.88%
PT rev (1m)0.89%
PT rev (3m)-0.19%
EPS NQ rev (1m)1.33%
EPS NQ rev (3m)1.16%
EPS NY rev (1m)0.47%
EPS NY rev (3m)0.11%
Revenue NQ rev (1m)1.36%
Revenue NQ rev (3m)1.3%
Revenue NY rev (1m)0.37%
Revenue NY rev (3m)0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.5 | ||
| Fwd PE | 23.74 | ||
| P/S | 8.92 | ||
| P/FCF | 24.68 | ||
| P/OCF | 24.22 | ||
| P/B | 3.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.55 |
EPS(TTM)10.96
EY3.92%
EPS(NY)11.77
Fwd EY4.21%
FCF(TTM)11.33
FCFY4.05%
OCF(TTM)11.54
OCFY4.13%
SpS31.32
BVpS78.18
TBVpS-6.01
PEG (NY)2.55
PEG (5Y)2.97
Graham Number138.85
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROCE | 24.11% | ||
| ROIC | 18.72% | ||
| ROICexc | 20.09% | ||
| ROICexgc | 151.85% | ||
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A | ||
| FCFM | 36.16% |
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
ROICexc(3y)17.24%
ROICexc(5y)12.98%
ROICexgc(3y)263.94%
ROICexgc(5y)202.43%
ROCE(3y)20.37%
ROCE(5y)15.39%
ROICexgc growth 3Y53.64%
ROICexgc growth 5Y25.03%
ROICexc growth 3Y41.34%
ROICexc growth 5Y22.06%
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.84 | ||
| Debt/EBITDA | 0.36 | ||
| Cap/Depr | 23.26% | ||
| Cap/Sales | 0.68% | ||
| Interest Coverage | 66.76 | ||
| Cash Conversion | 44.34% | ||
| Profit Quality | 109.88% | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | N/A |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)29.97%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.86%
Profit Quality(3y)106.99%
Profit Quality(5y)105.5%
High Growth Momentum
Growth
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
EPS Next Y9.98%
EPS Next 2Y7.13%
EPS Next 3Y6.89%
EPS Next 5Y7.92%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%
Revenue Next Year6.33%
Revenue Next 2Y5.53%
Revenue Next 3Y5.51%
Revenue Next 5Y4.71%
EBIT growth 1Y12.23%
EBIT growth 3Y39.48%
EBIT growth 5Y19.95%
EBIT Next Year12.32%
EBIT Next 3Y7.91%
EBIT Next 5Y7.1%
FCF growth 1Y23.34%
FCF growth 3Y16.49%
FCF growth 5Y8.18%
OCF growth 1Y22.71%
OCF growth 3Y15.38%
OCF growth 5Y6.67%
CME GROUP INC / CME FAQ
What is the ChartMill fundamental rating of CME GROUP INC (CME) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CME.
What is the valuation status of CME GROUP INC (CME) stock?
ChartMill assigns a valuation rating of 3 / 10 to CME GROUP INC (CME). This can be considered as Overvalued.
Can you provide the profitability details for CME GROUP INC?
CME GROUP INC (CME) has a profitability rating of 7 / 10.
What is the earnings growth outlook for CME GROUP INC?
The Earnings per Share (EPS) of CME GROUP INC (CME) is expected to grow by 9.98% in the next year.
Can you provide the dividend sustainability for CME stock?
The dividend rating of CME GROUP INC (CME) is 5 / 10 and the dividend payout ratio is 104.85%.